Entry Inhibitors in Development

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Show Archived (Historical) Articles

Fusion and Attachment Inhibitors (October 24, 2008)
To read PDF, click here
From AIDS InfoNet
Incyte Halts Development of Promising New CCR5 Drug (April 10, 2008)
From Project Inform
CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc (February 3, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Schering-Plough Launches Phase III Trials of Experimental Antiretroviral Vicriviroc (September 19, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Tests on HIV Drug Bring Good Results (May 4, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy (December 19, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
No Difference in HAART Response in Patients With X4-Using HIV (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Aplaviroc's Potency Against HIV Is Linked to Its Slow Dissociation From the CCR5 Receptor (August 17, 2006)
In XVI International AIDS Conference
Co-Receptor Conundrum: The Challenges of Turning Theory Into Reality (April 2006)
At the moment, there are many more questions than answers about an investigational class of drugs known as co-receptor inhibitors.
To read PDF, click here
In TAGline, from Treatment Action Group
Entry Inhibitors: The Ups and Downs of Drug Development (Spring 2006)
AIDS activist Lynda Dee offers her take on the successes and failures of this new class of drugs.
To read PDF, click here
In ACRIA Update, from AIDS Community Research Initiative of America
Entry Inhibitors in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.